Spectroscopic Magnetic Resonance Imaging of Glioma

Last updated: February 13, 2025
Sponsor: University of Minnesota
Overall Status: Trial Not Available

Phase

N/A

Condition

Neurofibromatosis

Cancer

Brain Tumor

Treatment

MEGA-PRESS sequence Magnetic Resonance Spectroscopy

Clinical Study ID

NCT03677999
NEUROSURG-2018-26848
  • Ages > 18
  • All Genders

Study Summary

The study is designed to develop and test new Magnetic Resonance Imaging methods that can improve the characterization of brain cancer and facilitate improved clinical care of these participants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Men and women scheduled who are diagnosed with glioma who is seeking clinical carefor their conditions at the UMN Masonic cancer center.

  2. Passed the safety screen for MRI

  3. Age 18 or older

  4. Ability to read and understand English

  5. Ability to provide informed consent

Exclusion

Exclusion Criteria:

  1. Participants who are excluded from the base MRI scan, as determined by the CMRR/CCIRclinical policies are necessarily excluded from this study, as the MRI scan will notbe performed.

  2. Pregnant women

Study Design

Treatment Group(s): 1
Primary Treatment: MEGA-PRESS sequence Magnetic Resonance Spectroscopy
Phase:
Study Start date:
June 01, 2019
Estimated Completion Date:
September 14, 2025

Study Description

The primary objective of this study is to develop and test new Magnetic Resonance Imaging methods that can improve the characterization of brain cancer and facilitate improved clinical care of these participants. More specifically, investigators are interested in applying novel spectroscopic and quantitative MR methods that give information beyond what is produced by a clinical brain MRI study and to understand the clinical correlates of the imaging findings. Investigators have tested these sequences in healthy volunteers. The investigators now wish to test these sequences in brain cancer participants in order to understand how these sequences can best be applied in a clinical setting.

To acquire these data, investigators intend to perform additional MRI acquisitions on participants who are scheduled to receive a clinical MRI at the UMN Center for Clinical Imaging Research (CCIR), a facility located at the Center for Magnetic Resonance Research (CMRR). Since these MRIs are required for the participants' clinical care, the participant will not be making additional visits to the CCIR. Based on published data and pilot experiences reported from other institutions, the sequences are well-tolerated. The only imposition for the participant is that the participant will spend additional time in the scanner after completion of the imaging required for clinical care. An informed consent form describing the additional MR sequences performed will be presented to the participant.

Connect with a study center

  • University of Minnesota

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.